

Epinex' Patent Granted for Revolutionary Diabetes Test



Epinex's patent for a "rapid test for glycosylated albumin" was issued by the United States Patent and Trademark Office (USPTO) on February 9, 2010.

Several U.S. [clinical studies](#) have demonstrated that monthly diabetes management is effective in reducing costs and improving outcomes. Diabetes currently costs the U.S. over \$113 billion annually, and costs are projected to triple over the next 25 years. Monthly G1A™ testing has the potential to bring about substantial cost reductions in diabetes care, fewer patient complications, and improved quality of life for over 250 million diabetics worldwide.

About Epinex Diagnostics, Inc.

Epinex Diagnostics is a private medical device company that develops innovative point-of-care diagnostic tests for patients and doctors. Please visit <http://www.epinex.com> for more information.

Contact

Jacqueline Morales
Public Relations
14351 Myford Road, Unit J
Tustin, CA 92780
949-660-7770
jacqueline@epinex.com

Tustin, California, March 01, 2010 – The United States Patent and Trademark Office (USPTO) granted Epinex Diagnostics the patent for its primary technology, the G1A™ [Rapid Diabetes Monitoring Index Test](#). The patent (US7659107B2) is for the first ever *rapid* glycosylated albumin test and instrument, which could redefine the way diabetes is monitored for over 250 million diabetics worldwide.

The G1A™ test provides a *monthly* diabetes-monitoring index by measuring damage caused by excess sugar to albumin, the most abundant serum protein. Albumin is an ideal *monthly* marker as it is replaced in the body every 2-3 weeks. Using only a pinprick of blood, the test will simultaneously and rapidly measure glycosylated albumin and total albumin. Researchers at the Wake Forest University School of Medicine have described glycosylated albumin as a "more robust" and "more accurate" indicator of long-term glycemic control.

There is an unmet need for a better test to monitor diabetes. Diabetics currently monitor themselves with multiple daily blood glucose tests, and HbA1c testing every 4-6 months. Scientific studies have demonstrated that current monitoring methods for type 2 diabetics (95% of all diabetics), are [ineffective](#) due to low compliance rates, physiological interference with accuracy, and delayed time frames for therapeutic interventions.

The innovative G1A™ test is unaffected by the factors that render current monitoring methods inadequate. Epinex's ground-breaking patent is the first step in establishing a [new standard of care](#) for diabetes, providing a *monthly* measurement of the protein damage that causes diabetes complications such as blindness, kidney failure, and heart disease. "Doctors will no longer have to wait 4-6 months to see if treatments are working," explains [Asad Zaidi](#), Epinex's CEO. "The G1A™ test will allow doctors and patients to adjust their therapeutic and lifestyle interventions on a monthly basis instead."